You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 11,154,509

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,154,509 protect, and when does it expire?

Patent 11,154,509 protects RAYALDEE and is included in one NDA.

This patent has fifty-three patent family members in sixteen countries.

Summary for Patent: 11,154,509

Patent landscape, scope, and claims:

Title:	Methods for controlled release oral dosage of a vitamin D compound
Abstract:	A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Inventor(s):	Bishop; Charles W. (Miami Beach, FL), Tabash; Samir P. (Whitby, CA), Agudoawu; Sammy A. (Mississauga, CA), White; Jay A. (Newmarket, CA), Crawford; Keith H. (Lone Tree, CO), Messner; Eric J. (Lake Forest, IL), Petkovich; P. Martin (Kingston, CA)
Assignee:	EIRGEN PHARMA LTD. (Waterford, IE) OPKO RENAL, LLC (Miami, FL)
Application Number:	15/726,046
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,154,509

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes	11,154,509	⤷ Subscribe				TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3 OR 4 CKD WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,154,509

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2481400	⤷ Subscribe	301085	Netherlands	⤷ Subscribe
European Patent Office	2481400	⤷ Subscribe	122020000079	Germany	⤷ Subscribe
European Patent Office	2481400	⤷ Subscribe	CA 2020 00059	Denmark	⤷ Subscribe
European Patent Office	2481400	⤷ Subscribe	C02481400/01	Switzerland	⤷ Subscribe
European Patent Office	2481400	⤷ Subscribe	132021000000071	Italy	⤷ Subscribe
European Patent Office	2481400	⤷ Subscribe	C202130022	Spain	⤷ Subscribe
Canada	2683997	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.